Reciprocal roles of angiotensin II and angiotensin II receptors blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: Possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis

International Journal of Molecular Sciences

Volumn 12, Issue 7, 2011, Pages 4206-4213

  Guan, Xiao Xu ^a   Zhou, Yi ^a   Li, Ji Yao ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiotensin ii; Arb; Camp; Cbfa1; Hypertension; Osteoporosis; Rankl

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLIC AMP; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR RUNX2; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST;

ARTICLE; CELL DIFFERENTIATION; DRUG MECHANISM; DRUG TARGETING; FRACTURE; HORMONE ACTION; HUMAN; HYPERTENSION; MOLECULAR PATHOLOGY; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; REGULATORY MECHANISM; RISK REDUCTION; SIGNAL TRANSDUCTION; BLOOD; CHEMISTRY; COMPLICATION; DRUG EFFECTS; METABOLISM; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALIA;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYCLIC AMP; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; NITRIC OXIDE; OSTEOPOROSIS; RANK LIGAND; RECEPTOR, ANGIOTENSIN, TYPE 2; SIGNAL TRANSDUCTION;

EID: 79960800979     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12074206     Document Type: Article

References (49)

1. Keen, R. Osteoporosis: Strategies for prevention and management. Best Pract. Res. Clin. Rheumatol. 2007, 21, 109-122.
2. Rodan, G.A.; Martin, T.J. Therapeutic approaches to bone disease. Science 2000, 289, 1508-1514.
3. Hanley, D.A.; Brown, J.P.; Tenenhouse, A.; Olszynski, W.P.; Ioannidis, G.; Berger, C.; Prior, J.C.; Pickard, L.; Murray, T.M.; Anastassiades, T.; et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J. Bone Miner. Res. 2003, 18, 784-790.
4. Woo, J.; Kwok, T.; Leung, J.; Tang, N. Dietary intake, blood pressure and osteoporosis. J. Hum. Hypertens. 2009, 23, 451-455.
5. Resnick, L.M.; Laragh, J.H.; Sealey, J.E.; Alderman, M.H. Divalent cations in essential hypertension: relations between serum ionized calcium, magnesium, and plasma renin activity. N. Engl. J. Med. 1983, 309, 888-891.
6. Cappuccio, F.P.; Kalaitzidis, R.; Duneclift, S.; Eastwood, J.B. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J. Nephrol. 2000, 13, 169-177.
7. Lynn, H.; Kwok, T.; Wong, S.Y.; Woo, J.; Leung, P.C. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006, 38, 584-588.
8. Shimizu, H.; Nakagami, H.; Osako, M.K.; Nakagami, F.; Kunugiza, Y.; Tomita, T.; Yoshikawa, H.; Rakugi, H.; Ogihara, T.; Morishita, R. Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens. Res. 2009, 32, 786-790.
9. Izu, Y.; Mizoguchi, F.; Kawamata, A.; Hayata, T.; Nakamoto, T.; Nakashima, K.; Inagami, T.; Ezura, Y.; Noda, M. Angiotensin II type 2 receptor blockade increases bone mass. J. Biol. Chem. 2009, 284, 4857-4864.
10. Asaba, Y.; Ito, M.; Fumoto, T.; Watanabe, K.; Fukuhara, R.; Takeshita, S.; Nimura, Y.; Ishida, J.; Fukamizu, A.; Ikeda, K. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J. Bone Miner. Res. 2009, 24, 241-250.
11. Rejnmark. L.; Vestergaard, P.; Mosekilde, L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: A nationwide case-control study. J. Hypertens. 2006, 24, 581-589.
12. Shimizu, H.; Nakagami, H.; Osako, M.K.; Hanayama, R.; Kunugiza, Y.; Kizawa, T.; Tomita, T.; Yoshikawa, H.; Ogihara, T.; Morishita, R. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008, 22, 2465-2475.
13. Teitelbaum, S.L. Bone resorption by osteoclasts. Science 2000, 289, 1504-1508.
14. Tintut, Y.; Parhami, F.; Tsingotjidou, A.; Tetradis, S.; Territo, M.; Demer, L.L. 8-Isoprostaglandin E2 enhances receptor-activated NFK{green}B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J. Biol. Chem. 2002, 277, 14221-14226.
15. Tintut, Y.; Parhami, F.; Le, V.; Karsenty, G.; Demer, L.L. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. J. Biol. Chem. 1999, 274, 28875-28879.
16. McFarlane, S.I.; Muniyappa, R.; Shin, J.J.; Bahtiyar, G.; Sowers, J.R. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 2004, 23, 1-10.
17. Parhami, F.; Morrow, A.D.; Balucan, J.; Leitinger, N.; Watson, AD.; Tintut, Y.; Berliner, J.A.; Demer, L.L. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 680-687.
18. Gjesdal, C.G.; Vollset, S.E.; Ueland, P.M.; Refsum, H.; Drevon, C.A.; Gjessing, H.K.; Tell, G.S. Plasma total homocysteine level and bone mineral density: The Hordaland Homocysteine Study. Arch. Intern. Med. 2006, 166, 88-94.
19. Parhami, F.; Basseri, B.; Hwang, J.; Tintut, Y.; Demer, L.L. High-density lipoprotein regulates calcification of vascular cells. Circ. Res. 2002, 91, 570-576.
20. Silva, T.A.; Garlet, G.P.; Fukada, S.Y.; Silva, J.S.; Cunha, F.Q. Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. J. Dent. Res. 2007, 86, 306-319.
21. Fox, S.W.; Chambers, T.J.; Chow, J.W. Nitric oxide is an early mediator of the increase in bone formation by mechanical stimulation. Am. J. Physiol. Endocrinol. Metab. 1996, 270, E955-E960.
22. Aguirre, J.; Buttery, L.; O'Shaughnessy, M.; Afzal, F.; Fernandez de Marticorena, I.; Hukkanen, M.; Huang, P.; MacIntyre, I.; Polak, J. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am. J. Pathol. 2001, 158, 247-257.
23. Li, D.Y.; Zhang, Y.C.; Philips, M.I.; Sawamura, T.; Mehta, J.L. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ. Res. 1999, 84, 1043-1049.
24. Morawietz, H.; Rueckschloss, U.; Niemann, B.; Duerrschmidt, N.; Galle, J.; Hakim, K.; Zerkowski, H.R.; Sawamura, T.; Holtz, J. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999, 100, 899-902.
25. Yu, X.; Murao, K.; Imachi, H.; Cao, W.M.; Li, J.H.; Matsumoto, K.; Nishiuchi, T.; Ahmed, R.A.M.; Wong, N.C.W.; Kosaka, H.; Unterman, T.G.; Ishida, T. Regulation of scavenger receptor class BI gene expression by angiotensin II in vascular endothelial cells. Hypertension 2007, 49, 1378-1384.
26. Andreozzi, F.; Laratta, E.; Sciacqua, A.; Perticone, F.; Sesti, G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ. Res. 2004, 94, 1211-1218.
27. Sen, U.; Herrmann, M.; Herrmann, W.; Tyagi, S.C. Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling. Clin. Chem. Lab. Med. 2007, 4, 1771-1776.
28. MacGregor, G.A.; Cappuccio, F.P. The kidney and essential hypertension: a link to osteoporosis? J. Hypertens. 1993, 11, 781-785.
29. Neelon, F.A.; Birch, B.M.; Drezner, M.; Lebovitz, H.E. Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. Lancet 1973, 1, 631-633.
30. Hokland, B.M.; Slotte, J.P.; Bierman, E.L.; Oram, J.F. Cyclic AMP stimulates efflux of intracellular sterol from cholesterol-loaded cell. J. Biol. Chem. 1993, 268, 25343-25349.
31. Mattaliano, M.D.; Huard, C.; Cao, W.; Hill, A.A.; Zhong, W.Y.; Martinez, R.V.; Harnish, D.C.; Paulsen, J.E.; Shih, H.H. LOX-1-dependent transcriptional regulation in response to oxidized LDL treatment of human aortic endothelial cells. Am. J. Physiol. Cell Physiol. 2009, 296, C1329-C1337.
32. Chang, P.Y.; Luo, S.; Jiang, T.; Lee, Y.T.; Lu, S.C.; Henry, P.D.; Chen, C.H. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation 2001, 104, 588-593.
33. Pullamsetti, S.S.; Savai, R.; Schaefer, M.B.; Wilhelm, J.; Ghofrani, H.A.; Weissmann, N.; Schudt, C.; Fleming, I.; Mayer, K.; Leiper, J.; et al. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation 2011, 123, 1194-1204.
34. Zou, T.; Liu, W.J.; Li, S.D.; Zhou, W.; Yang, J.F.; Zou, C.G. TRB3 mediates homocysteine-induced inhibition of endothelial cell proliferation. J. Cell. Physiol. 2010, DOI: 10.1002/jcp.22554.
35. Kubalak, S.W.; Webb, J.G. Angiotensin II enhancement of hormone-stimulated cAMP formation in cultured vascular smooth muscel cells. Am. J. Physiol. 1993, 264, H86-H96.
36. Cola, C.; Almeida, M.; Li, D.; Romeo, F.; Mehta, J.L. Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem. Biophys. Res. Commun. 2004, 320, 424-427.
37. Thaler, R.; Spitzer, S.; Rumpler, M.; Fratzl-Zelman, N.; Klaushofer, K.; Paschalis, E.P.; Varga, F. Differential effects of homocysteine and beta aminopropionitrile on preosteoblastic MC3T3-E1 cells. Bone 2010, 46, 703-709.
38. Lin, I.C.; Smartt, J.M., Jr.; Nah, H.D.; Ischiropoulos, H.; Kirschner, R.E. Nitric oxide stimulates proliferation and differentiation of fetal calvarial osteoblasts and dural cells. Plast. Reconstr. Surg. 2008, 121, 1554-1566.
39. Hagiwara, H.; Hiruma, Y.; Inoue, A.; Yamaguchi, A.; Hirose, S. Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. J. Endocrinol. 1998, 156, 543-550.
40. Franceschi, R.T. The developmental control of osteoblast-specific gene expression role of specific transcription factors and the extracellualr matrix enviromment. Crit. Rev. Oral. Biol. Med. 1999, 10, 40-57.
41. Luegmayr, E.; Glantschnig, H.; Wesolowski, G.A.; Gentile, M.A.; Fisher, J.E.; Rodan, G.A.; Reszka, A.A. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ. 2004, 11, S108-S118.
42. Tintut, Y.; Morony, S.; Demer, L.L. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler. Thromb. Vasc. Biol. 2004, 24, e6-e10.
43. Nenseter, M.S.; Ueland, T.; Retterstol, K.; Strom, E.; Morkrid, L.; Landaas, S.; Ose, L.; Aukrust, P.; Holven, K.B. Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects: Effect of treatment with B-vitamins. Stroke 2009, 40, 241-247.
44. Fan, X.; Roy, E.; Zhu, L.; Murphy, T.C.; Ackert-Bicknell, C.; Hart, C.M.; Rosen, C.; Nanes, M.S.; Rubin, J. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. Endocrinology 2004, 145, 751-759.
45. Nishiya, Y.; Sugimoto, S. Effects of various antihypertensive drugs on the function of osteoblast. Biol. Pharm. Bull. 2001, 24, 628-633.
46. Fliser, D.; Buchholz, K.; Haller, H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110, 1103-1107.
47. Watanabe, T.; Suzuki, J.; Yamawaki, H.; Sharma, V.K.; Sheu, S.S.; Berk, B.C. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: Angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 2005, 112, 1798-1805.
48. Papadakis, J.A.; Mikhailidis, D.P.; Vrentzos, G.E.; Kalikaki, A.; Kazakou, I.; Ganotakis, E.S. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin. Appl. Thromb. Hemost. 2005, 11, 139-146.
49. Kohno, M.; Yokokawa, K.; Kano, H.; Yasunari, K.; Minami, M.; Hanehira, T.; Yoshikawa, J. Adrenomedullin is a potent inhibitor of angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertension 1997, 29, 1309-1313.